Business
Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma
Progression free survival (PFS) of 74% at 16 months compares favourably to standard of care PFS of 50% at 11.5 months 1 Strong PFS consistent across key subgroups Reaffirms selection of iSCIB1+ and target HLA population for late-stage development Early overall survival (OS) data, most advanced for SCIB1, showing a 14% improvement at 26 months over SoC1 In advanced planning for registrational trials with positive scientific advice from regulators To hold late-breaking oral presentation on SCOPE t
About this update from Scancell Holdings Plc
[{"type":"image","alt":"Scancell Holdings Plc","displaySize":"","headline":null,"caption":"Scancell Holdings Plc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":54,"url":"https://media.zenfs.com/en/globenewswire.com/b13bc6685f23fb28f74542b8ae6c6fee"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FhJvhpDXvP8ngfWe1NUy2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b13bc6685f23fb28f74542b8ae6c6fee","width":300,"height":54}},"lazy":false},{"type":"text","content":"Progression free survival (PFS) of 74% at 16 months compares favourably to standard of care PFS of 50% at 11.5 months 1","length":124,"tagName":"p"},{"type":"text","content":"Strong PFS consistent across key subgroups","length":42,"tagName":"p"},{"type":"text","content":"Reaffirms selection of iSCIB1+ and target HLA population for late-stage development","length":83,"tagName":"p"},{"type":"text","content":"Early overall survival (OS) data, most advanced for SCIB1, showing a 14% improvement at 26 months over SoC1","length":112,"tagName":"p"},{"type":"text","content":"In advanced planning for registrational trials with positive scientific advice from regulators","length":99,"tagName":"p"},{"type":"text","content":"To hold late-breaking oral presentation on SCOPE trial at ESMO IO conference","length":76,"tagName":"p"},{"type":"text","content":"Investor webinar on Thursday 11th December 2025 at 2.00pm GMT","length":66,"tagName":"p"},{"type":"text","content":"NOTTINGHAM, United Kingdom, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of active immunotherapies to treat cancer, announces updated positive data from the SCOPE Phase 2 trial of iSCIB1+ in combination with ipilimumab and nivolumab, current standard of care (SoC). A late-breaking abstract on the data has been released, and an additional poster presentation will be made during an oral session at the ESMO Immuno-Oncology Congress 2025 (ESMO IO) conference on 11th December 2025.","length":529,"tagName":"p"},{"type":"text","content":"Results from SCOPE to date have enabled Scancell to select Immunobody iSCIB1+, administered needle-free intramuscularly, for further development in patients with selected human leukocyte antigen (HLA) alleles ("the target population"), representing 80% o...